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Abstract
Patients with cystic fibrosis (CF) have elevated concentration of cytokines in sputum and a general inflammatory condition.
In addition, CF cells in culture produce diverse cytokines in excess, including IL-1b. We have previously shown that IL-1b, at
low doses (,30 pM), can stimulate the expression of CFTR in T84 colon carcinoma cells, through NF-kB signaling. However,
at higher doses (.2.5 ng/ml, ,150 pM), IL-1b inhibit CFTR mRNA expression. On the other hand, by using differential
display, we found two genes with reduced expression in CF cells, corresponding to the mitochondrial proteins CISD1 and
MTND4. The last is a key subunit for the activity of mitochondrial Complex I (mCx-I); accordingly, we later found a reduced
mCx-I activity in CF cells. Here we found that IB3-1 cells (CF cells), cultured in serum-free media, secrete 32365 pg/ml of IL-
1b in 24 h vs 12763 pg/ml for S9 cells (CFTR-corrected IB3-1 cells). Externally added IL-1b (5 ng/ml) reduces the mCx-I
activity and increases the mitochondrial (MitoSOX probe) and cellular (DCFH-DA probe) ROS levels of S9 (CFTR-corrected
IB3-1 CF cells) or Caco-2/pRSctrl cells (shRNA control cells) to values comparable to those of IB3-1 or Caco-2/pRS26 cells
(shRNA specific for CFTR). Treatments of IB3-1 or Caco-2/pRS26 cells with either IL-1b blocking antibody, IL-1 receptor
antagonist, IKK inhibitor III (NF-kB pathway) or SB203580 (p38 MAPK pathway), restored the mCx-I activity. In addition, in
IB3-1 or Caco-2/pRS26 cells, IL-1b blocking antibody, IKK inhibitor III or SB203580 reduced the mitochondrial ROS levels by
,50% and the cellular ROS levels near to basal values. The AP-1 inhibitors U0126 (MEK1/2) or SP600125 (JNK1/2/3 inhibitor)
had no effects. The results suggest that in these cells IL-1b, through an autocrine effect, acts as a bridge connecting the
CFTR with the mCx-I activity and the ROS levels.
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Introduction
Cystic fibrosis (CF) is an autosomal recessive disease caused by
mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene [1,2], which encodes a chloride channel
expressed at the apical surface of secretory epithelia [3,4]. More
than 1930 mutations have been identified in the CFTR gene [5].
The most common mutation, a deletion of three bases encoding a
phenylalanine at position 508 (DF508), generates a misfolded
CFTR protein. Consequently, the endoplasmic reticulum retains
most of the CFTR, which then suffers proteasomal degradation
[6,7].
After the CFTR was cloned [1,2] most studies were focused on
non-genomic effects of CFTR. Little was known regarding its own
gene regulation, except for effects of cAMP through CREB [8],
and the enhanced mRNA degradation induced by TNF-a [9] or
interferon-c (but not interferon-a or b) [10]. Searching for other
possible regulators of CFTR gene expression, we tested the effects
of TGF-b1 and IL-1b. These particular proteins were selected
because we had previously observed effects of TGF-b1 on other
channels (calcium channels) [11,12] and IL-1b usually had
opposed effects to TGF-b1 [13]. Interestingly, we found that IL-
1b, at doses up to 0.5–1.0 ng/ml (,30–60 pM), was able to
stimulate CFTR mRNA and protein expression, constituting the
first extracellular upregulator known for CFTR [14,15]. Although
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we did not further explore the effects of TGF-b1, later it was
reported by Howe et al. that TGF-b1 down-modulates CFTR, an
effect that was reverted by inhibitors of p38 MAPK, but not by
inhibitors of JNK, ERK1/2 MAPK, or PI3K [16,17]. Notewor-
thy, the response of CFTR to IL-1b was biphasic and, at doses over
2.5 ng/ml, IL-1b was inhibitory for the CFTR mRNA expression.
In addition, the CFTR protein stimulation seen with lower IL-1b
doses (,0.5 ng/ml or 30 pM) was no longer observed in this
second, inhibitory phase [15]. The first phase of CFTR response
to IL-1b involved the NF-kB pathway [18]. The second phase has
not been studied in detail yet, although preliminary data suggest
that the JNKR c-Jun RAP-1 pathway is involved [19]. Since the
amount of IL-1b reported in sputum of CF patients (2.8–32 ng/
ml) [20] is higher than the lowest in vitro inhibitory dose of 2.5 ng/
ml, the IL-1b present in lungs should be enough to down-regulate
CFTR, and it might had profound negative effects on the already
reduced amounts of DF508 CFTR able to reach the cell
membrane. Previously, Di Mango et al. had found elevated NF-
kB activity and IL-8 production in CF cell lines [21]. It was later
found that CFTR inhibition results on activation of NF-kB [22–
24] and that several cytokines [25–31], including IL-1b [32], were
upregulated in cultured CF cells. On the other hand, Velsor et al.
found an altered glutathione balance and oxidative stress in CF
cells [33], in agreement with earlier work of Burton Shapiro et al.
[34](recently reviewed in [35]). Thus, excess of cytokines and a
redox imbalance appear to be important characteristics of CF
cells.
Soon after the CFTR was cloned it appeared evident certain
lack of correlation between the CF genotype and the complex
phenotype of the disease. We thought that this complex phenotype
might be the consequence of a net of genes with altered expression
due to the CFTR failure. Testing this hypothesis by using
differential display, we found several CFTR-dependent genes [36–
40]. Other laboratories found similar results by using microarrays
[41–43]. One of the upregulated CFTR-dependent genes resulted
to be SRC/c-Src. Since it was known that c-Src regulated the
expression of several mucins, we thought that it might constitute a
bridge between the CFTR failure and the overexpression of
mucins in CF [38]. However, we know today that the CFTR R
MUC pathway is more complex, since additional factors other
than SRC/c-Src regulate mucins [44,45]. Later, looking for
differentially expressed genes that contrary to SRC showed a
reduced expression in CF cells, we characterized two of them and,
surprisingly, both resulted in genes codifying for mitochondrial
proteins: CISD1 (nuclear genome) [40] and MTND4 (mitochon-
drial genome) [39]. Noteworthy, MTND4 had been reported as
essential for the assembly and proper activity of mitochondrial
Complex I (mCx-I) [46]. Due to the MTND4 downregulation we
observed in CF cells [39], we hypothesized that mCx-I activity
should be also affected in CF cells or in cells with impaired CFTR
function. In fact, we found later a reduced activity of mCx-I in CF
cells or wt-CFTR treated with CFTR inhibitors or transfected
with CFTR-shRNA [47]. Thus, a causal relationship between the
CFTR and the mCx-I activities was demonstrated, although the
mechanism was largely unknown [47]. These results were also in
agreement with earlier reports of Burton Shapiro and colleagues
[48–53], work that had been disregarded when the CFTR was
cloned and found to be a chloride channel (reviewed in [35]).
In addition, pro-inflammatory cytokines, as IL-1b and TNF-a,
are known to regulate mitochondrial function in human cardio-
myocytes [54] and chondrocytes [55], inducing a reduced activity
of mCx-I. Since it had been observed that IB3-1 cells in serum free
culture media overexpressed IL-1b mRNA [32], we thought that
the reduced activity of mCx-I found in CF cells might be mediated
by increased levels of secreted IL-1b, somehow modulated by the
CFTR activity. In agreement with this idea, here we show that IL-
1b, through an autocrine effect, is responsible for the inhibition of
the mCx-I and partially responsible for the increased reactive
oxygen species (ROS) levels found in IB3-1 CF cells or in Caco-2/
pRS26 cells (transfected with CFTR shRNA). These effects on
mCx-I and ROS levels were reversed by using an anti-IL-1b
monoclonal antibody able to block IL-1b signaling, interleukin-1
receptor antagonist (IL1RN) or by using pharmacological inhib-
itors of NF-kB activation (IKK inhibitor III/BMS-345541) or p38
MAPK (SB203580), but not by using inhibitors of JNK
(SP600125) or MEK1/2 (U0126) kinases.
Materials and Methods
Reagents
Interleukin-1 beta (IL-1b) (Cat. No. I9401), IL-1 receptor
antagonist (Cat. No. SRP3327), pepstatin, PMSF, leupeptin,
Figure 1. Interleukin-1 beta expression in IB3-1 and S9 cells.
IB3-1 and S9 cells were preincubated for 24 h in serum-free DMEM/F12
plus 24 h in the presence of a CFTR-stimulating cocktail and the cellular
IL-1b mRNA and protein levels were determined. A: Quantitative real-
time RT-PCR of IL-1b mRNA expression levels in S9 e IB3-1 cells. B:
Immune-dot blotting quantification of the IL-1b present in culture
media. The results were expressed as pg/ml in the conditioned media,
after 24 h of culture. Measurements were performed in duplicate and
data are expressed as mean 6 SE of three independent experiments
(n = 3). *indicates p,0.05.
doi:10.1371/journal.pone.0099257.g001
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dimethyl sulfoxide (DMSO, culture grade), NADH, dibutyryl-
cAMP, lauryl-maltoside, IBMX, (2)-isoproterenol hydrochloride,
protease inhibitor cocktail (Cat. No. P2714) and rotenone were
purchased from Sigma-Aldrich (St. Louis, MO). Cytochrome c
from equine heart (Cat. No. 250600), and IKK inhibitor III
(BMS-345541) were from Calbiochem (San Diego, CA). MAPK1/
p38 inhibitor (SB203580), MAPKK (MEK1/2) inhibitor (U0126)
and JNK inhibitor (SP600125) were from Alomone Labs
(Jerusalem, Israel). Bis-Tris, 6-aminohexanoic/e-aminocaproic
acid and nitroblue tetrazolium (NBT) were from Fluka (Sigma-
Aldrich). NBT/BCIP mixture was from Promega (Madison, WI),
and Coomassie Brilliant Blue G-250 was from Bio-Rad Labora-
tories (Hercules, CA). MitoSOX (Molecular Probes Cat. No.
M36008), 29,79-dichlorofluorescein diacetate (DCFH-DA, Molec-
ular Probes Cat. No. D399) and ROX (glycine conjugate of 5-
carboxy-X-rhodamine, succinimidyl ester, Invitrogen Cat.
No. 12223-012) were from Life Technologies Corporation (Carls-
bad, CA). All other reagents were analytical grade. Antibodies:
goat anti-mouse antibody coupled to alkaline phosphatase (goat
polyclonal, sc-2008), goat anti-rabbit antibody coupled to alkaline
phosphatase (goat polyclonal, sc-2007), mouse anti-ubiquinol-
cytochrome c reductase core protein I (UQCRC1) (16D10 mAb,
IgG1, sc-65238), mouse anti-NF-kB p65 (F-6 mAb, IgG1, sc-8008),
mouse anti-IkB-a (H-4 mAb, IgG1, sc-1643), mouse anti p-p38
(D-8 mAb, IgM, sc-7973), mouse anti-p38a/b (A-12 mAb, IgG1,
sc-7972), mouse anti-histone H1 (AE-4 mAb, IgG2a, sc-8030), and
mouse anti-JNK2 (A-7 mAb IgG1, sc-271133) were from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA); mouse anti-IL-1b
(mAb, IgG1, I3642; the antibody neutralizes the biological activity
of recombinant human IL-1b) and rabbit anti-actin antibody
(polyclonal, A2066) were from Sigma-Aldrich.
Cell Cultures
IB3-1 cells (ATCC CRL-2777, a bronchial cell line derived
from a cystic fibrosis patient with a DF508/W1282X CFTR
genotype) [56] and S9 cells (ATCC CRL-2778, which are IB3-1
cells transduced with an adeno-associated viral vector to stably
express wt-CFTR) [57] were purchased from ATCC (www.atcc.
org) (these cell lines are no longer provided by ATCC; they are
kept now at the John Hopkins University Cell Center). Caco-2/
pRS26 cells that stably express a shRNA plasmid directed against
CFTR and Caco-2/pRSctrl control cells (HuSH 29-mer shRNA
Non-Effective Expression Plasmid against GFP as negative
control; OriGene Rockville, MD) were cultured as previously
described [47] adding 1 mg/ml puromycin. All cells were cultured
in DMEM/F12 (Life Technologies, GIBCO BRL products,
Rockville, MD) supplemented with 5% FBS (Fetal Bovine
Serum)(PPA GmbH, Austria), 100 units/ml penicillin, 100 mg/
ml streptomycin, and 0.25 mg/ml amphotericin B (Life Technol-
ogies, GIBCO BRL, Rockville, MD). Cells were seeded at a
density of 20,000 cells/cm2 (p150 dishes have ,140 cm2) and
cultured for 24 h in 15 ml (0.107 ml/cm2) DMEM-F12 plus 5%
FBS, at 37uC in a humidified air atmosphere containing 5% CO2.
Before treatments, cells were cultured 24 hours in serum-free
medium. Then, the serum-free media was replaced and the cells
were cultured for additional 24 h (S9 and IB3-1 cells in the
presence of a CFTR-stimulation cocktail: 200 mM dibutyryl-
cAMP, 200 mM IBMX and 20 mM isoproterenol). The different
Figure 2. Effect of IL-1b on mitochondrial Complex I activity
(mCx-I). IB3-1 and S9 cells pre-incubated in serum free media for 24 h
were incubated for additional 24 h (plus CFTR-stimulating cocktail) in
the presence or absence of IL-1b (5 ng/ml) and the mCx-I activity was
determined. A: mCx-I in-gel activity (IGA) of treated and untreated S9
and IB3-1 cells; mCx-III correspond to the WB for the UQCRC1 subunit of
the mitochondrial complex III used as internal standard. B: Densito-
metric quantification and statistical analysis of the results shown in
panel A (for n = 3); IGA of mCx-I was calculated as the ratio mCx-I IGA/
mCx-III WB. C: Spectrophotometric measurements of mitochondrial
NADH-cytochrome c reductase activity for the same experiments shown
in panel A and B. Results were expressed as percentage (%) relative to
S9 control values. Measurements were performed in triplicate and data
were expressed as mean 6 SE of three independent experiments
(n = 3). *indicates p,0.05 compared with basal S9 cells.
doi:10.1371/journal.pone.0099257.g002
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treatments (IL-1b, anti-IL1b, IL-1 receptor antagonist and
inhibitors) were performed in this second 24 h period, in serum
free media. The media volume used was always 0.107 ml/cm2.
Reverse Transcription and Quantitative Real-time PCR
(qRT-PCR) for IL-1b
The IB3-1 and S9 cells were cultured 72 h as above indicated,
and total RNA isolated by using a guanidinium thiocyanate-
phenol-chloroform extraction solution [58]. The quality of RNA
was checked by electrophoresis in denaturing formaldehyde
agarose gels [59], and measuring the ratios A260/A230 (greater
than 2) and A260/A280 nm (from 1.7 to 2.0). Total RNA samples
(1.5 mg) were transcribed by using M-MLV Reverse Transcriptase
(Promega) and Oligo-dT12, according to the manufacturer’s
instructions (100 U of RT/mg of RNA). Quantitative real-time
RT-PCRs (qRT-PCR) were performed by using an ABI 7500 real-
time PCR system (Applied Biosystems Inc., Foster City, CA); the
DDCt method was used for comparative quantification. TBP (Tata
Box Binding Protein) was used as an internal control. Primer
sequences for PCR were as follows: TBP, 59-TGCACAGGAGC-
CAAGAG TGAA-39 (forward) and 59-CACATCACAGCTCCC-
CACCA-39 (reverse); IL-1b, 59-ACAGAT-
GAAGTGCTCCTTCCA-39 (forward) and 59-
GTCGGAGATTCGTAGCTGGAT-39 (reverse). The cDNA
samples (10 ml of a 1:10 of cDNA from reverse-transcribed
RNA) were added to 25 ml of PCR reaction mixture containing a
final concentration of 2.5 mM MgCl2, 0.4 mM deoxynucleotide
triphosphates, 1 U of Go Taq DNA polymerase (Promega), 0.1 X
EvaGreen (Biotium, Hayward, CA), 50 nM ROX as reference
dye, and 0.2 mM of each primer. The qRT-PCR conditions were
as follows: initial denaturation at 95uC for 10 min, followed by 40
cycles at 95uC for 30 s, 62uC for 30 s and 72uC for 30 s.
Fluorescence signal was acquired at the elongation step, at the end
of each cycle. qRT-PCR reactions were carried out in triplicates
(intra- and inter-assays by triplicate). The final quantification
values were obtained as the mean of the Relative Quantification
(RQ) for each biological triplicate (n = 3).
Secretion of IL-1b
Secreted IL-1b was measured in conditioned media from IB3-1
cells, S9 cells, Caco-2/pRS26 cells and Caco-2/pRSctrl control
cells. Each cell lines was cultured 72 h as above indicated in five
p150 dishes (the last 24 h in 10 ml of serum free media, except for
S9 and IB3-1 cells which also have CFTR stimulation cocktail).
The media were collected and concentrated by centrifugation at
35006g for 30 min at 4uC; by using the Amicon Ultra-15
centrifugal filter units (10.000 kDa cut-off, EMD Millipore,
Billerica, MA). Protein concentration was determined by Lowry
[60]. Then, an immune-dot blotting procedure previously
described by Sun et al. [61] was applied to determine the IL-1b
levels in the concentrated medium, with some modifications.
Briefly, the concentrated samples (150 mL derived from 50 ml of
conditioned media) and different amounts of recombinant IL-1b
(0, 0.3125, 0.625, 0.125, 2.5 and 5 ng) were slowly filtered through
Figure 3. Recovery of mCx-I activity by incubation with anti-IL-1b blocking antibody or with IL-1b receptor antagonist (IL1RN). S9
and IB3-1 cells preincubated for 24 h in serum free media were additionally incubated for 24 h (in the presence of a CFTR-stimulating cocktail) with
anti-IL-1b blocking antibody or IL-1 receptor antagonist. The mCx-I activity was determined by using spectrophotometric measurements of the
mitochondrial NADH-cytochrome c reductase activity. A: IB3-1 cells were treated with anti-IL-1b blocking antibody (30 ng/ml) or IL-1 receptor
antagonist (10 ng/ml). The Figure shows the activity expressed as percentage (%), considering the average activity of S9 cells as 100%. Ab-Ctrl: anti-
JNK2 monoclonal antibody as negative control (30 ng/ml). B: Spectrophotometric measurements of mitochondrial NADH-cytochrome c reductase
activity of IB3-1 cells treated with increasing concentrations of anti-IL-1b blocking antibody (0, 1, 5, 15 and 30 ng/ml). C: Spectrophotometric
measurements of mitochondrial NADH-cytochrome c reductase activity of IB3-1 cells treated with increasing concentrations of IL-1 receptor
antagonist (0, 1, 5, 10 and 50 ng/ml). Measurements were performed in triplicate and data were expressed as mean 6 SE of three independent
experiments (n = 3). *indicates p,0.05 compared with basal IB3-1 cells.
doi:10.1371/journal.pone.0099257.g003
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a nitrocellulose membrane by using the Easy-Titer ELIFA System
(Thermo Scientific Pierce, Rockford, IL) [62–64]. The membranes
were then blocked with 5% BSA in TBS (25 mM Tris, 150 mM
NaCl, pH 7.0), washed with TBS, and incubated with a
monoclonal antibody raised against IL-1b (Sigma I3642, dilution
1:1000 in TBS plus Tween-20, 0.05% v/v). After 3 h incubation
with the primary antibody, the membranes were washed three
times with TBS plus Tween-20 (0.05% v/v) for 5 min. Then, the
membranes were incubated with a secondary goat IgG anti-mouse
antibody coupled to alkaline phosphatase (Santa Cruz Biotech-
nology, sc2008, dilution 1:1000), washed three times with TBS
plus Tween-20 (0.05% v/v) for 5 min and developed with the
substrates NBT-BCIP, following the manufacturer’s instructions
(Promega). The membranes were scanned (HP ScanJet G3110
scanner) and the signal intensities quantified by densitometry by
using the NIH Image software, Java version (ImageJ, rsbweb.-
nih.gov). Finally, densitometry values were used to calculate the
IL-1b amounts through interpolation into the standard curve of
IL-1b (0–5 ng/ml), and were expressed as concentration values
(pg/ml and pM).
Mitochondria Isolation
Mitochondria were isolated by using differential centrifugation,
according to Majander et al. [65], with minor modifications [47].
Briefly, cells were incubated 72 h as above indicated (see Cell
cultures section). After treatment, cells were maintained at 0–4uC
(over ice/water), washed with cold PBS, scrapped in the presence
of 1 ml PBS with protease inhibitors (10 mM pepstatin, 10 mM
leupeptin, 100 mM PMSF, 1 mM EDTA) and centrifuged at
6006g, 5 min at 4uC. The pellet was resuspended in isolation
buffer (0.25 M sucrose, 25 mM MOPS, pH 7.4, plus the same
protease inhibitors added to PBS), diluted to 250 mg/ml, and the
cells were permeabilized by adding 0.12% w/v digitonin for 30 s
on ice. The sample was diluted in three volumes of isolation buffer
and centrifuged at 10,0006g for 20 min at 4uC. The resultant
pellet was resuspended in 500 ml of isolation buffer and
centrifuged at 8006g for 10 min at 4uC. The supernatant was
centrifuged at 10,0006g for 20 min at 4uC, to collect the
mitochondria. The mitochondrial pellet was resuspended in 10–
20 ml of BN-sample buffer A (1 M aminocaproic acid, 50 mM Bis-
Tris-HCl, 10 mM pepstatin, 10 mM leupeptin, 100 mM PMSF,
1 mM EDTA, pH 7.0). Mitochondrial protein concentration was
measured by the Lowry’s method by using aliquots of mitochon-
drial extract incubated with 0.1 N NaOH for 30 min at 37uC, to
dissolve mitochondrial membranes [60].
Blue Native PAGE (BN-PAGE)
The BN-PAGEs were performed according to Scha¨gger et al.
[66], with minor modifications [47]. Mitochondrial protein
samples were resuspended in BN-sample buffer A (see above) to
a final protein concentration of 3 mg/ml, and then solubilized
adding lauryl maltoside (0.6% w/v, final concentration). The
mixture was then centrifuged at 20,0006g for 30 min at 4uC.
Before loading the gel, BN-sample buffer B containing Coomassie
Brilliant Blue G-250 (CBB G-250) (1 M aminocaproic acid, 20%
glycerol, 50 mM Bis-Tris-HCl, 5% w/v CBB G-250, pH 7.0) was
added to the samples at a final ratio 1:14 v/v. Samples (80 mg of
protein) were electrophoresed in a 5–13% BN-PAGE gradient gel
containing a 4% stacking gel. Electrophoresis was carried out at
80 V, at 4uC, until protein samples migrated into the stacking gel.
Figure 4. MEK1/2 inhibition. After 24 h in serum free media, IB3-1
cells were incubated for 24 h with increasing concentrations of the
MAPK/AP-1 pathway inhibitor U0126 (1, 5, 10 and 20 mM) and the mCx-I
activity was measured by using BN-PAGE and spectrophotometry. A:
mCx-I in-gel activity (IGA) and mCx-III Western blotting (WB). B:
Densitometric quantification and statistical analysis of the results
shown in panel A, calculated from three independent experiments
(n = 3). IGA of mCx-I was calculated as the ratio mCx-I (IGA)/mCx-III (WB).
C: Spectrophotometric measurements of the mitochondrial NADH-
cytochrome c reductase activity in the same experiments of panel A,
expressed as percentage (%) relative to S9 control values. Measure-
ments were performed in triplicate and data were expressed as mean6
SE of three independent experiments (n = 3). *indicates p,0.05
compared with basal IB3-1 cells.
doi:10.1371/journal.pone.0099257.g004
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Figure 5. JNK inhibition. IB3-1 cells preincubated for 24 h in serum
free media were additionally incubated for 24 h with increasing
concentrations of the JNK inhibitor SP600125 (1, 5, 10 and 20 mM)
and the mCx-I activity was measured by using BN-PAGE and
spectrophotometry. A: mCx-I in-gel activity (IGA) and mCx-III (WB). B:
Densitometric quantification and statistical analysis of the results shown
in panel A. IGA of mCx-I was calculated as the ratio mCx-I (IGA)/mCx-III
(WB). C: Spectrophotometric measurements of the mitochondrial
NADH-cytochrome c reductase activity in samples obtained from the
same experiments of panel A, expressed as percentage (%) relative to
S9 control values. Measurements were performed in triplicate and data
were expressed as mean 6 SE of three independent experiments
(n = 3). *indicates p,0.05 compared with basal IB3-1 cells.
doi:10.1371/journal.pone.0099257.g005
Figure 6. P38/MAPK1 inhibition. After 24 h in serum free media,
IB3-1 cells were incubated for 24 h with increasing concentrations of
the p38 MAPK inhibitor SB203580 (1, 5, 10 and 20 mM) and mCx-I
activity was measured by using BN-PAGE and spectrophotometry. A:
mCx-I in-gel activity (IGA) and mCx-III (WB). B: Densitometric
quantification and statistical analysis of the results shown in panel A.
IGA of mCx-I was calculated as the ratio mCx-I (IGA)/mCx-III (WB). C:
Spectrophotometric measurements of the mitochondrial NADH-cyto-
chrome c reductase activity in the same experiments of panel A,
expressed as percentage (%) relative to S9 control values. Measure-
ments were performed in triplicate and data were expressed as mean6
SE of three independent experiments (n = 3). *indicates p,0.05
compared with basal IB3-1 cells.
doi:10.1371/journal.pone.0099257.g006
CFTR, Complex I, ROS and Autocrine IL-1b
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Then, the voltage was set to 200 V with a current limited to
15 mA (voltage 200R400 volts), at 4uC. Once the trace dye had
migrated half-way into the separation gel, the cathode (2) buffer
(50 mM Tricine, 15 mM Bis-Tris-HCl, 0.02% CBB G-250,
pH 7.0) was replaced with the same buffer without CBB G-250,
in order to reduce the background of gels [47].
Measurement of Mitochondrial Complex I (mCx-I) in-gel
Activity (IGA) and Western Blotting of Mitochondrial
Proteins
To measure the mCx-I (IGA) at the end of the run, the upper
section of the separation gel (around 2 cm), containing the mCx-I,
was incubated for 20–40 min in development buffer (0.1 M Tris-
HCl, 0.14 mM NADH, 1.22 mM NBT, pH 7.4). To stop the
reaction and distain the CBB background, a fixing solution (45%
methanol: 10% acetic acid in water) was used. In parallel, the
inferior section of the gel was transferred to a PVDF membrane
using a transfer buffer without methanol (39 mM glycine, 48 mM
Tris-base, 0.037% sodium dodecyl sulfate (SDS), pH 8.3) for 2.5 h
at 100 V (constant voltage). The membranes were blocked with
5% BSA 1 h in TBS buffer and incubated with a monoclonal
antibody raised against the ubiquinol-cytochrome c reductase core
protein I (UQCRC1), a subunit of the mitochondrial complex III
(mCx-III, EC 1.10.2.2) (mAb sc-65238 from Santa Cruz
Biotechnology; dilution 1:500 in TBS plus Tween-20, 0.05% v/
v). After 3 h incubation with the primary antibody, the
membranes were washed three times with TBS plus Tween-20
(0.05% v/v) for 5 min. Then, the membranes were incubated with
a secondary goat IgG anti-mouse antibody coupled to alkaline
phosphatase (mAb sc-2008 from Santa Cruz Biotechnology;
dilution 1:1000 in TBS plus Tween-20, 0.05% v/v), washed three
times with TBS plus Tween-20 (0.05% v/v) for 5 min and
developed with the substrates NBT-BCIP following the manufac-
turer’s instructions (Promega). Membranes and gels were scanned
and the signal intensities quantified by using the Image J software.
The mCx-I activity was referred to the UQCRC1 values, used as
internal controls. This subunit was used as internal standard since
its concentration remained constant with the different treatments.
Spectrophotometric Assay of Mitochondrial NADH-
cytochrome C Reductase Activity
To measure the mCx-I activity using cytochrome c as an
natural electron acceptor instead of NBT (used for BN-PAGE), we
measured the NADH-cytochrome c reductase activity (mCx-I plus
mCx-III) spectrophotometrically, in the presence/absence of
rotenone (10 mM) (Sigma R8875), an specific inhibitor of mCx-I,
as it was previously described by others [67,68], with minor
modifications. Briefly, mitochondrial preparations were subjected
to three freeze-thaw cycles to make them permeable to substrates.
To measure the mCx-I activity, mitochondria (equivalent to
100 mg of proteins; to obtain consistent results it is important not
to use less than 100 mg) were resuspended in a buffer solution
(100 mM H2KPO4/HK2PO4, 0.5 mM KCN, 200 mM NADH,
25 mM cytochrome c, pH 7.4) and the reduction of cytochrome c
was recorded as absorbance/min at 550 nm, for 2 min at and
30uC. To calculate the enzyme activity, inhibition of NADH
cytochrome c reductase activity by rotenone (10 mM) was
measured in parallel for each sample after 5 min of preincubation
with the inhibitor, and the remaining values (insensitive to
rotenone) were subtracted from the total activity. Then, the results
were expressed as percentages, considering the activity in control
cells as 100%. The measurement of mCx-I and mCx-III activities
in a chain reaction (NADHRmCx-IRmCx-IIIRcytochrome c) is
Figure 7. NF-kB pathway inhibition. S9 and IB3-1 cells were
preincubated for 24 h in serum-free media and then the IB3-1 cells were
incubated for additional 24 h in the presence of increasing concentra-
tions of IKK inhibitor III (1, 2, 5 and 10 mM). A: mCx-I in-gel activity (IGA)
and mCx-III (WB). B: Densitometric quantification and statistical analysis
of the results shown in panel A. IGA of mCx-I was calculated as the ratio
mCx-I IGA/mCx-III WB. C: Spectrophotometric measurements of the
mitochondrial NADH-cytochrome c reductase activity in the same
experiments of panel A, expressed as percentage (%) relative to S9
control values. Measurements were performed in triplicate and data
were expressed as mean 6 SE of three independent experiments
(n = 3). *indicates p,0.05 compared with basal IB3-1 cells.
doi:10.1371/journal.pone.0099257.g007
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a good indicative that the respiratory chain complexes remain
intact after mitochondrial isolation and also provides a way to use
a natural electron acceptor as cytochrome c instead of NBT,
reinforcing the results of BN-PAGEs.
Subcellular Fractionation to Determine NF-kB and p38
Activities
A subcellular fractionation was performed as previously
described by Wier et al. [69]. Briefly, cells were incubated as
above indicated. Then, cells were washed twice with cold PBS,
scraped with 1 ml cold PBS with protease inhibitors (10 mM
pepstatin, 10 mM leupeptin, 100 mM PMSF, 1 mM EDTA), and
centrifuged at 6006g for 10 min at 4uC. The cell pellet was
resuspended in 500 ml of buffer containing 10 mM HEPES,
1.5 mM MgCl2, 10 mM KCl, 0.5 mM fresh dithiothreitol (DTT),
0.4% NP-40, and protease inhibitor cocktail (Sigma-Aldrich
P2714), pH 7.9, for 5 min at 4uC. The cell lysate/nuclear
suspensions were prepared by centrifugation at 5006g for 3 min
at 4uC, and supernatants were collected as cytosolic fractions.
Then, the pellets were resuspended in nuclear extraction buffer
(20 mM HEPES, 0.4 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
25% glycerol, 0.5 mM DTT and protease inhibitor cocktail,
pH 7.9). The samples were kept on ice for 10 min, and centrifuged
at 14,0006g for 10 min at 4uC. The supernatant was used as the
nuclear extract and stored at 280uC before use. The protein
concentration was determined by Lowry [60].
Western Blot Analysis of NF-kB and p38
Western blots (WB) were performed as previously described
[18]. Briefly, nuclear and cytosolic extracts (30–50 mg of proteins)
were separated on a denaturing SDS-PAGE (12%) and transferred
to nitrocellulose membranes. Cytosolic proteins were analyzed for
p-p38, p38, IkB-a and actin, and nuclear proteins were analyzed
for NF-kB p65 subunit and histone H1. Membranes were blocked
with BSA 5% in TBS 1 h and then incubated with primary
monoclonal antibodies against NF-kB p65 subunit, IkB-a and p-
p38 (Santa Cruz Biotechnology; sc-8008, sc-1643, sc-7973,
respectively; dilutions 1:500 in TBS plus Tween-20, 0.05% v/v)
for 3 h. The membranes were washed three times with TBS plus
Tween-20 (0.05% v/v) for 5 min and incubated for 1 h with goat
IgG anti-mouse antibody coupled to alkaline phosphatase (mAb
sc-2008 from Santa Cruz Biotechnology; dilution 1:1000 in TBS
plus Tween-20, 0.05% v/v), washed three times with TBS plus
Tween-20 (0.05% v/v) for 5 min and developed with the
substrates NBT-BCIP following the manufacturer’s instructions
(Promega). As internal controls, membranes were reincubated with
anti-actin antibody (Sigma-Aldrich, A2066, dilution 1:1000), anti-
p38 (Santa Cruz Biotechnology; sc-7972, dilution 1:500) or anti-
histone H1 (Ab AE-4, sc-8030, Santa Cruz Biotechnology, dilution
1:500), washed three times as above indicated and then incubated
for 1 h with goat IgG anti-mouse antibody coupled to alkaline
phosphatase (mAb sc-2008 from Santa Cruz Biotechnology;
dilution 1:1000 in TBS plus Tween-20, 0.05% v/v) or goat IgG
anti-rabbit antibody coupled to alkaline phosphatase (mAb sc-
2007 from Santa Cruz Biotechnology; dilution 1:1000 in TBS plus
Tween-20, 0.05% v/v) as secondary Ab for actin. Membranes
were developed as mentioned before and scanned. The signal
intensities were quantified by using the Image J software.
Measurement of Mitochondrial and Cellular ROS Levels
Mitochondrial and cellular ROS levels were measured by using
fluorescent probes in 96 well black plates (Greiner Bio-One,
Germany; 655090). The cells were cultured 72 h as above
indicated and treated the last 24 h with IL-1b, anti-IL-1b blocking
monoclonal antibodies or inhibitors of JNK (SP600125), MAPK1/
p38 (SB203580), MAPKK/MEK1/2 (U0126), and IKK (IKK
inhibitor III). To measure mitochondrial ROS levels, at the end of
incubation, the DMEM-F12 medium was changed to Hank’s
medium (136.9 mM NaCl, 5.4 mM KCl, 1.3 mM CaCl2, 3.7 mM
NaH2PO4, 0.4 mM KH2PO4, 4.2 mM NaHCO3, 0.7 mM
MgSO4, 5.5 mM D-glucose and 10 mM HEPES) containing
5 mM of MitoSOX [70] (stock prepared as 5 mM solution in
DMSO) and incubated at 37uC in the 5% CO2/air incubator for
10 min. Cellular ROS levels were measured by using the
fluorescent probe DCFH-DA in Hank’s medium containing
10 mM of the fluorescent probe (stock prepared as 20 mM
solution in DMSO) and incubated at 37uC in the 5% CO2/air
incubator for 40 min. Then, cells were washed with 0.2 ml of
Hank’s buffer three times and the fluorescence was measured in a
fluorescence plate reader (NOVOstar BMG LABTECH GmbH
Ortenberg, Germany) with incubation at 37uC. Filters were
Ex = 510610 nm, Em = 580610 nm for MitoSOX and
Ex = 510610 nm, Em = 540610 nm for DCFH-DA, and read-
ings were performed by using 10 cycles (3 flashes per well and
cycle, excitation and measurements done from the bottom of the
plate).
Statistics
Unless otherwise indicated, the assays were performed at least
by duplicates and the experiments were repeated at least three
times. The results were expressed as the media obtained from the
different independent experiments (interassay comparisons). One-
way ANOVA and the Tukey’s test were applied to calculate
significant differences among samples (a= 0.05). All values are
indicated as mean 6 SE (n). *indicates significant differences (p,
0.05).
Results
Expression of Interleukin-1 Beta in IB3-1and S9 Cells
In order to test whether in our cultured conditions (serum
starvation plus CFTR stimulation) IB3-1 cells overexpress IL-1b
compared to S9 cells (which are IB3-1 CF cells rescued by ectopic
expression of wt-CFTR), we measured the relative levels of IL-1b
mRNA and protein. As shown in Figure 1A, expression of IL-1b
mRNA was significantly increased (.400%; p,0.05) in IB3-1 cells
Figure 8. P38 and NF-kB activation in S9 and IB3-1 cells. Cells were preincubated 24 h in serum free media and then incubated with IL-1b
(5ng/ml), anti-IL-1b blocking antibody (Ab-IL-1b) (30 ng/ml), p38 inhibitor SB203580 (p38 Inh) (5 mM), or IKK inhibitor III (IKK Inh) (2 mM), for another
24 h in serum-free media. A: Representative WB of phospho-p38 (p-p38) and total p38 of whole cellular lysates from S9 an IB3-1 cells. B:
Densitometric quantification and statistical analysis of p38 phosphorylation status (calculated as the p-p38/p38 ratios for each experimental
condition). C: Representative WB of NF-kB p65 and histone H1 from nuclear extracts of S9 and IB3-1 cells. D: Densitometric quantification and
statistical analysis of the results shown in panel C (calculated as p65/histone ratio for each experimental condition). E: Representative WB of IkB-a and
actin of whole cellular lysates from S9 and IB3-1 cells. F: Densitometric quantification and statistical analysis of the results shown in panel C
(calculated as IkB-a/actin ratio for each experimental condition). The results were expressed as percentage (%) relative to S9 control values.
Measurements were performed in triplicate and data are expressed as mean 6 SE of three independent experiments (n = 3). *indicates p,0.05
compared to basal IB3-1 cells.
doi:10.1371/journal.pone.0099257.g008
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compared to S9 cells. These results were in agreement with the
values reported by Bartling et al. for the same cell lines [32]. In
addition, a significant although less pronounced increment was
observed for the secreted protein, accumulated during 24 h of
culture: 12763 pg/ml (n = 2)(,7.3 pM) for S9 cells and
32365 pg/ml (n = 2)(,18.5 pM) for IB3-1 cells (2.5 fold increase,
p.0.05), as shown in Figure 1B. The secretion rate was 2.7 fmol/
106cell/h or 15.7 fg/ml/mg/h (mg of total proteins in the culture
media) for IB3-1 and 1.1 fmol/106cell/h or 6.5 fg/ml/mg/h for
S9 cells (assuming a constant rate over the 24 h period).
Exogenous IL-1b Affects the Mitochondrial Complex I
(mCx-I) Activity
We have previously found that the mCx-I activity was reduced
approximately 50% in CF cells or in cells with impaired CFTR-
function (inhibitors, shRNA), cultured for 24 h in serum-free
media [47]. In the presence of FBS, differences in mCx-I activity
were not observed (data not shown). Now, to study the possible
role of IL-1b in the reduced mCx-I activity of CF cells, we first
tested whether the addition of exogenous IL-1b might reduce the
mCx-I activity of S9 and IB3-1 cells. Both cell lines were incubated
with 5 ng/ml of IL-1b for 24 h in serum-free medium (in presence
of CFTR-stimulating cocktail). As shown in Figure 2, the mCx-I
in-gel activity (IGA) of S9 cells was significantly reduced (p,0.05),
as compared to untreated control cells. However, no significant
differences (p.0.05) were observed between IL-1b treated and
untreated IB3-1 cells. Similar results were found when the
mitochondrial NADH-cytochrome c reductase activity was mea-
sured spectrophotometrically, as shown in Figure 2C. It should be
pointed-out however, that the reduction in the NADH-cyto-
chrome c reductase activity of IB3-1 cells compared to S9 cells was
variable, in a range between 20% and 50%. To avoid this
problem, at least 100 mg of total protein should be used for the
assays. Altogether, these results confirm that IB3-1 cells, have a
reduced mCx-I activity, and demonstrate that exogenous added
IL-1b is able to reduce the mCx-I in S9 cells (which are CFTR-
corrected IB3-1 cells). The results were in agreement with previous
reports showing that IL-1b impaired the mCx-I activity in
cardiomyocytes [54] and chondrocytes [71].
The lack of response to exogenous IL-1b (5 ng/ml) obtained
with IB3-1 cells suggests that these cells might have already a
saturated IL-1b signaling, probably due to the presence of secreted
IL-1b in abundance (with a saturated autocrine signaling). In this
regard, the IL-1b concentration in the conditioned media of IB3-1
cells after 24 h was 323 pg/ml (18.5 pM), which is three times less
than the concentration required for maximal mCx-I inhibition in
S9 cells (,57 pM or 1 ng/ml) [72]. However, the actual
concentration of IL-1b in the cell surrounding volume should be
several times higher than in the total volume of the conditioned
media, as it was similarly observed for ATP secretion and signaling
[73,74].
Recovery of mCx-I Activity by Incubation with Anti-IL-1b
Blocking mAb or IL-1 Receptor Antagonist
To confirm the presence of an autocrine IL-1b secretion in IB3-
1 cells and its possible effect on the mitochondrial mCx-I activity,
we used an anti-IL-1b monoclonal antibody (IgG1 isotype) or the
IL-1 receptor antagonist (IL1RN) to block the IL-1b binding to its
receptor [75,76]. As shown in Figure 3, treatment of IB3-1 cells
with increasing concentrations of blocking antibody (cells incu-
bated 24 h in serum-free medium in presence of CFTR-
stimulating cocktail plus different Ab concentrations) or IL1RN
results in a significant (p,0.05) increment of the mitochondrial
NADH-cytochrome c reductase activity sensitive to rotenone.
Dose-response curves for the IL-1b blocking Ab and the IL1RN
are shown in Figures 3B and 3C (IL-1b blocking Ab
Figure 9. ROS levels in IB3-1 and S9 cells. S9 and IB3-1 cells were
preincubated 24 h in serum free media. Then, the media was replaced
(serum free, in the presence of a CFTR-stimulating cocktail) and the cells
incubated another 24 h. The IB3-1 cells were treated in this second
incubation as indicated. IL-1b: IL-1b (5 ng/ml); Ab-IL-1b: anti-IL-1b
blocking antibody (30 ng/ml); Ab-Ctrl: anti-Histone H1 monoclonal
antibody as negative control for antibody incubation (30 ng/ml); p38
Inh: p38 inhibitor SB203580 (5 mM); IKK Inh: IKK inhibitor III (2 mM); JNK
Inh: JNK inhibitor SP600125 (5 mM); MEK1/2 Inh: MAPK/AP-1 pathway
inhibitor U0126 (5 mM). A: MitoSOX fluorescence (5 mM for 10 min in
Hank’s buffer). B: DCF fluorescence (10 mM DCFH-DA for 40 min in
Hank’s buffer); Ab-Ctrl: anti-JNK2 monoclonal antibody as negative
control. Results were expressed as percentage (%) relative to S9 control
values. Measurements were performed in triplicate and data are
expressed as mean 6 SE of three independent experiments (n = 3).
*indicates p,0.05 compared to IB3-1 cells.
doi:10.1371/journal.pone.0099257.g009
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ED50 = 8.7663.59 ng/ml or ,0.06 nM; IL1N
ED50 = 2.7063.11 ng/ml or ,0.15 nM). These results are in
agreement with previous observations of Verhaeghe et al. showing
the presence of an autocrine IL-1b loop in cultured epithelial
CFT-2 and 16HBE CF cells, which could be disrupted by using
anti-IL-1b blocking antibodies [77]. Noteworthy, the IL-1b
blocking Ab (5 ng/ml and over) and the IL-1RN were able to
rescue the mCx-I activity of IB3-1 cells to values very close to those
observed in S9 cells as a reference. In other words, a complete
recovery of the mCx-I activity seems to occur in the presence of
the blocking Ab or IL1RN. By the contrary, control antibodies
anti-JNK (IgG1) (Fig. 3A) or anti-Histone (IgG2a, data not shown)
showed no effects over basal mCx-I activity. These results
reinforce the idea that secreted IL-1b (Fig. 1) is acting as an
autocrine factor affecting the mCx-I activity in CF cells.
Figure 10. Il-1b secretion, Mitochondrial NADH cytochrome c reductase activity and ROS levels in stable CFTR knock down cells.
Caco-2/pRSctrl cells (transfected with pRS control) and Caco-2/pRS26 cells (transfected with the shRNA pRS26) were preincubated 24 h in serum free
media. A: Immune-dot blotting quantification of the IL-1b present in culture media. The results were expressed as pg/ml. B: Cells were treated for
additional 24 h, as indicated. IL-1b: IL-1b (5 ng/ml); Ab-IL-1b: anti-IL-1b blocking antibody (30 ng/ml); Ab-Ctrl: anti-Histone H1 monoclonal antibody
as negative control (30 ng/ml); p38 Inh: p38 inhibitor SB203580 (5 mM); IKK Inh: IKK inhibitor III (2 mM); JNK Inh: JNK inhibitor SP600125 (5 mM); MEK1/
2 Inh: MAPK/AP-1 pathway inhibitor U0126 (5 mM). Spectrophotometric measurements of the mitochondrial NADH-cytochrome c reductase activity,
expressed as percentage (%) relative to Caco-2/pRS26 control values. C: Mitochondrial ROS levels in the same experiments of panel B; the figure
shows the MitoSOX fluorescence (5 mM for 10 min in Hank’s buffer). Results were expressed as percentage (%) relative to Caco-2/pRSctrl control
values. D: Cellular ROS levels in the same experiments of panel B; the figure shows the DCF fluorescence (DCFH-DA 10 mM for 40 min in Hank’s
buffer). Results were expressed as percentage (%) relative to Caco-2/pRSctrl control values. Measurements were performed in triplicate and data are
expressed as mean 6 SE of two independent experiments (n = 2). *indicates p,0.05 compared to Caco-2/pRS26 cells.
doi:10.1371/journal.pone.0099257.g010
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Effects of IL-1b Pathway Inhibitors on the Reduced mCx-I
Activity of IB3-1 CF Cells
To reinforce the idea that an autocrine IL-1b signaling is
responsible for the inhibition of mCx-I activity in IB3-1 cells, in
addition to the anti-IL-1b blocking Ab we used four pharmaco-
logical inhibitors of key enzymes involved in IL-1b signaling. The
results obtained are described below.
Effects of MEK1/2 Inhibition on mCx-I Activity
MEK1/2 kinases belong to a p42/p44 branch of the IL-1b
signaling pathway. This branch, made by RAS, RAF, MEK1/2
and ERK1/2, forms a bridge between the IL-1b receptor I
signaling and the AP-1 transcription factor. In human and mouse
epidermis, the single disruption of MEK1 or MEK2 have no
effect, whereas double mutants abolish ERK1/2 phosphorylation,
leading to hypo-proliferation and apoptosis, effects that can be
rescued overexpressing ERK1/2 [78]. In order to inhibit MEK1/
2 kinases, we used the pharmacological inhibitor U0126. It has
been shown to inhibit MEK1/2 kinases with
Figure 11. Graphical summary for IL-1b effects on mCx-I activity and mitochondrial ROS levels in IB3-1 and Caco-2/pRS26. The figure
illustrates the interactions among the different proteins, kinases or small molecules involved in this work. The interactions were drawn by using the
software Pathway Studio (v 9, Elsevier). Arrows with the+symbol represent stimulations and those with the -| symbol represent inhibition. Green
ellipses: small molecules; red sickle-vertex: kinases; purple rectangle: disease (CF); blue star-vertex: shRNA specific for CFTR. The results obtained with
IL-1b blocking Ab or with the receptor inhibitor IL1RN suggest that an autocrine IL-1b signaling is responsible for the reduced mCx-I activity and the
increased ROS levels seen in IB3-1 CF cells or in Caco-2/pRS26 cells. Inhibition of NF-kB or p38 MAPK also resulted in increased mCx-I activity and
decreased ROS levels. The inhibition of MEK1/2 or JNKs (AP-1 pathway) had no effects. The mechanisms by which CFTR increases IL-1b and IL1-b, p38
MAPKs or NF-kB inhibit mCx-I and increase ROS levels remain to be determined (dotted lines).
doi:10.1371/journal.pone.0099257.g011
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IC50 = 0.07260.02 mM for MEK1 and IC50 = 0.05860.02 mM
for MEK2 [79]. The AP-1 activity was also inhibited in COS-7
cells incubated for 24 h in the presence of U0126 with an
IC50 = 0.9660.16 mM for [79]. Accordingly, we used different
doses of inhibitor starting at 1 mM to assure inhibition of AP-1
signaling. As shown in Figure 4, incubation of IB3-1 cells with up
to 20 mM of U0126 did not resulted in any improvement of the
low mCx-I activity of these cells. By the contrary, U0126 shows a
tendency to reduce the mCx-I activity of IB3-1 cells (more evident
in Fig. 4C than in Fig. 4B). Since the IC50 for AP-1 , 1 mM (and
less for MEK1/2) [79], these results suggest that the AP-1 pathway
(including MEK1/2 kinases) is not be involved in the autocrine
effects of IL-1b over the mCx-I activity.
Effects of JNK Inhibition on mCx-I Activity
Jun N-terminal kinases (JNKs) are stress kinases that can be
activated by inflammatory cytokines (including IL-1b), bacterial
endotoxin, osmotic shock, UV radiation and hypoxia [80].
SP600125 has been shown to inhibit Jun N-terminal kinases
(JNKs) and other kinases (IC50 = 40 nM for JNK1 and JNK2,
90 nM for JNK3 and 1.0–5.1 mM for p56Lck, MKK3/4/6/7,
PKB/AKT and PKCa [80]). In Jurkat cells, SP600125 blocks c-
Jun phosphorylation with an IC50 = 5–10 mM [80]. Therefore, we
used this inhibitor at concentrations ranging (1–20 mM). As shown
in Figure 5, increased concentrations of SP600125 were not able
to recover the reduced mCx-I activity of IB3-1 cells. These results,
as those obtained with U0126, also suggest that AP-1 signaling is
not involved in the autocrine effects of IL-1b over the mCx-I
activity.
Effects of p38 Inhibition on mCx-I Activity
The p38 mitogen-activated protein kinases are also activated by
different cellular stresses, bacterial lipopolysaccharide (LPS) and
inflammatory cytokines, including IL-1b [81]. These kinases are
also involved in the regulation of pro-inflammatory cytokine
expression [82]. There are four p38 MAPKs identified so far:
MAPK14/p38-a/SAPK2A, MAPK11/p38-b/SAPK2B,
MAPK12/p38-c/SAPK3 and MAPK13/p38-d/SAPK4.
SB203580 has been used to inhibit MAPK14/p38-a and
MAPK11/p38-b with IC50 = 50 nM and 500 nM respectively
[83,84]. At 10 mM the residual activity (% of control) was found to
be 261, 1061, 9662, and 9364 for the isoforms a to d,
respectively [83]. Therefore, the inhibitory effect occurs mostly
over the isoform a and to a lesser extends over the isoform b.
SB203580 also inhibited the serum withdrawal effects on COX-2
mRNA in MDA-MB-231 cells with IC50 , 10 mM, a value which
was higher than in monocytic cells and synoviocytes [85].
Therefore, we used SB203580 at concentrations ranging 1–
20 mM.
Contrary to the results shown above for MEK1/2 and JNK
inhibitors, the p38 SB203580 inhibitor was able to revert the low
mCx-I activity of IB3-1 cells. As shown in Figure 6, maximal
response to SB203580 was obtained at ,5 mM (24 h incubation).
Using BN-PAGE (Fig. 6A and 6B), the p38 inhibitor was able to
recover near 70% of the activity measured in S9 cells. On the
other hand, by using spectrophotometric measurements of the
mitochondrial NADH-cytochrome c reductase activity (Fig. 6C),
in the presence of 5 mM of inhibitor, the IB3-1 cells reached over
90% of the activity measured in S9 cells. Thus, near a full recovery
of the mCx-I activity of IB3-1 cells was obtained through p38
inhibition.
Effects of NF-kB Inhibition on mCx-I Activity of S9 and
IB3-1 Cells
As IL-1b exerts many of its biological effects by activating the
transcription factor nuclear factor-kappa B (NF-kB) [15,18,86], we
explored whether the inhibition of this signaling pathway can also
help to recover the mCx-I activity of IB3-1 cells. For this purpose
we used the IKK inhibitor III/BMS-345541, which inhibit IKK
(IkB kinase). It has IKK-2 IC50 , 0.3 mM and IKK-1 IC50 ,
4 mM [87], and inhibited the stimulated phosphorylation of IkB in
THP-1 in cells with IC50 , 4 mM [87]. Therefore, we used this
inhibitor at concentrations ranging (1–10 mM). As shown in
Figure 7 treatment of IB3-1 cells with IKK inhibitor III led to a
significant (p,0.05) increase on the mCx-I in-gel activity (IGA) as
compared to untreated control cells. Noteworthy, by using
spectrophotometry (Figure 7C), a complete recovery of the
mitochondrial NADH-cytochrome c reductase activity of IB3-1
cells was observed in the presence of IKK inhibitor III (compared
to S9 cells).
To make sure that p38 was activated in IB3-1 cells, the
phosphorylation status of p38 (p-p38) was tested by Western blots.
As shown in Figure 8A (WB) and 8B (quantification), the
phosphorylation of p38 was higher in IB3-1 CF cells than in S9
cells. The phosphorylation of p38 in IB3-1 cells stimulated with
IL-1b (5 ng/ml) was unaltered as compared to untreated IB3-1
cells, suggesting again that the autocrine IL-1b stimulus is enough
to saturate its signaling pathway. However, the phosphorylation of
p38 in IB3-1 cells treated with anti-IL-1b antibody or p38
inhibitor was significantly (p,0.05) decreased compared to IB3-1
untreated cells. The IKK inhibitor III also showed some reduction
on the p-p38 levels, although the differences were not significant
compared to basal IB3-1 p-p38 levels. Altogether, these results
reinforce the idea that autocrine IL-1b is responsible for the
reduced mCx-I activity observed in IB3-1 cells and suggest a
possible role of p38 MAPK in the autocrine effects of IL-1b over
the mCx-I activity.
To confirm the activation of NF-kB in IB3-1 cells, the relative
amount of p65 were measured by using Western blots of nuclear
extracts. As shown in Figure 8C and D, the amount of nuclear p65
was significantly increased (p,0.05) in basal IB3-1 cells compared
to S9 cells. This p65 levels were maintained in IB3-1 cells treated
with IL-1b (signal already saturated) or p38 inhibitor (no effect). In
contrast, as expected, p65 nuclear translocation in IB3-1 cells
treated with anti-IL-1b antibody or IKK inhibitor III was
decreased (p,0.05) compared to IB3-1 basal cells. Finally,
cytoplasmic IkBa showed the opposed behavior to p65, as
expected for NF-kB activation (Fig. 8E and F).
The results obtained with IKK inhibitor III, as those obtained
with the p38 inhibitor SB203580, or the IL1 b blocking Ab and
IL1RN, also reinforce the idea that autocrine IL-1b is responsible
for the reduction of mCx-I observed in IB3-1 cells and suggest that
the NF-kB also has a role in the IL-1b effects on the reduced mCx-
I activity of IB3-1 cells.
Mitochondrial and Cellular ROS Levels on S9 and IB3-1
Cells
It has been reported that inhibition of mCx-I might increase
ROS levels in certain cells and conditions [88,89]. Therefore, we
speculated that autocrine effects of IL-1b might also be responsible
for the increased ROS levels observed by other authors in IB3-1
cells [33]. As shown in Figure 9A, the mitochondrial ROS levels,
measured by using MitoSOX, were found significantly increased
(p,0.05) in IB3-1 cells compared to S9 cells, reflecting an
increased oxidative stress. Exogenously added IL-1b was not able
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to further increase ROS levels in IB3-1 cells, which again suggests
that the IL-1b pathway is already saturated in these cells, as it was
observed measuring the mCx-I activity. In addition, the anti-IL-1b
blocking monoclonal antibody was able to reduce ROS levels of
IB3-1 cells to near 50%. The IKK inhibitor III (2 mM) or the
MAPK1/p38 inhibitor, SB203580, (5 mM) had both a significant
inhibitory effect on the ROS levels of IB3-1 cells. On the other
hand, also as occurred with the inhibition of mCx-I activity, the
inhibitor of MEK1/2, U0126 (5 mM) and of JNKs, SP600125
(5 mM), were not able to modify mitochondrial ROS levels in IB3-
1 cells. Similar results were found when the cellular ROS levels
were measured by using the fluorescent probe DCFH-DA, as
shown in Figure 9B.
Effects of IL-1b and its Inhibitors on mCx-I Activity and
ROS Levels of Caco-2 Cells Transfected with shRNA
Specific for CFTR
To determine if the overexpression of IL-1b and the reduction
on the mCx-I activity observed in IB3-1 could also be observed in
a different cell system, we then used Caco-2 cells (which express
wt-CFTR) transfected with a control plasmid pRSctrl or with a
plasmid pRS26 containing a CFTR-specific shRNA. These stable
transfected cells were selected, cloned and characterized in a
previous work [47]. As shown in Figure 10A, secreted IL-1b was
significantly increased (, 190%) in Caco-2/pRS26 cells
(18764 ng/ml) compared to Caco-2/pRSctrl control cells
(9868 ng/ml). The secretion rate was 1.6 fmol/106cells/h
(13.9 fg/ml/mg/h) and 0.8 fmol/106cells/h (6.6 fg/ml/mg/h),
respectively. In addition, as shown in Figure 10B, the CFTR
shRNA induced a significant reduction of NADH cytochrome c
reductase activity in Caco-2/pRS26 cells compared to Caco-2/
pRSctrl control cells. The values were similar to those previously
reported for these stably-transfected cells [47].
When the Caco-2/pRSctrl control cells and Caco-2/pRS26
cells were incubated with 5 ng/ml of IL-1b, for 24 h in serum-free
medium, the mitochondrial NADH-cytochrome c reductase
activity in Caco-2/pRSctrl cells was significantly reduced (p,
0.05) compared to untreated Caco-2/pRSctrl cells. No significant
differences were observed between IL-1b treated and untreated
Caco-2/pRS26 cells, again in agreement with the idea that
autocrine IL-1b secretion was enough to saturate its own signaling.
As shown in Figure 10B, the IL-1b blocking antibody significantly
increased (p,0.05) the mitochondrial NADH-cytochrome c
reductase activity of Caco-2/pRS26 compared to the untreated
cells. Treatments of Caco-2/pRS26 cells with the IKK inhibitor
III (2 mM) or the p38 MAPKs inhibitor SB203580 (5 mM) led to a
significant increase on the mitochondrial NADH-cytochrome c
reductase activity as compared with untreated cells. In addition,
MEK1/2 and JNK inhibitors were ineffective in reversing the
reduced mitochondrial NADH-cytochrome c reductase activity.
These results are all in agreement with those obtained when the
same experiments were done by using IB3-1 and S9 cells (Fig. 2–
7).
We next studied the mitochondrial ROS levels in Caco-2/
pRSctrl (control cells) and CFTR knock-down Caco-2/pRS26
cells. As shown in Figure 10C, the mitochondrial ROS levels,
measured by using the mitochondrial ROS probe MitoSOX, were
found significantly increased in Caco-2/pRS26 cells compared to
Caco-2/pRSctrl control cells. Again, as occurred with IB3-1 cells,
exogenously added IL-1b was not able to further increase ROS
levels in Caco-2/pRS26 cells. Anti-IL-1b blocking monoclonal
antibody was able to significantly (p,0.05) reduce ROS levels of
Caco-2/pRS26 cells. Finally, the IKK inhibitor III (2 mM) and the
MAPK1/p38 inhibitor (SB203580) (5 mM) have a strong inhib-
itory effect on ROS levels of Caco-2/pRS26 cells. Once more, the
inhibitors of MAPKK/MEK1/2 (U0126, 5 mM) and JNK II
(SP600125, 5 mM), were not able to modify ROS levels in Caco-
2/pRS26 cells. Similar results were found when the cellular ROS
levels were measured by using the fluorescent probe DCFH-DA,
as shown in Figure 10D. However, the contribution of other
sources of ROS levels, beside mitochondria, such as the DUOX1/
2 system, cannot be ruled-out [90]. On the other hand, the higher
reduction observed in the cellular ROS (cROS) levels compared to
the mitochondrial ROS (mROS) levels in the presence of the IL-
1b blocking Ab might be in part due to effects of the scavenger
systems of cytoplasm, including glutathione, peroxiredoxin-6 and
superoxide dismutase [35], and not only due to a regulation in the
production of cROS and mROS. Taken together, all the results
obtained in Caco-2 cells are in agreement with those obtained with
IB3-1 cells. In conclusion, the inhibitors of p38 MAPKs and IKKs,
or the IL-1b blocking Ab and the IL1RN, were able to revert the
mCx-I activity and significantly reduce the ROS levels in cells with
impaired CFTR activity (IB3-1 and Caco-2/pRS26 cells).
Discussion
The aim of this work was to test the hypothesis that the reduced
mCx-I activity observed in CF cells or in cells with impaired
CFTR activity [35,47] could be at least partially attributed to an
autocrine effect [91,92] of IL-1b.
After verifying that in our culture conditions the IB3-1 cells
overexpressed IL-1b and had a reduced mCx-I activity, we
explored whether the IL-1b secreted by IB3-1 cells was responsible
for the mCx-I inhibition. For this purpose, the IB3-1 cells were
incubated in the presence of an anti-IL-1b monoclonal antibody,
which blocks the biological activity of IL-1b [93]. Noteworthy, in
the presence of blocking antibody, a significant and almost full
recovery of the mCx-I activity was observed for IB3-1 cells, with
values approaching those of S9 cells. Similar effects were observed
by using the interleukin-1 receptor antagonist peptide IL1RN
[94,95]. Thus, an autocrine [91,92] effect of IL1-b appears to be
responsible for the reduced mCx-I activity observed in IB3-1 cells.
Further evidence in support of this hypothesis was obtained by
using pharmacological inhibitors of different branches of the IL-1b
signaling pathway. The inhibitors U0126 (MEK1/2) and
SP600125 (JNKs) were not able to recover the mCx-I activity of
IB3-1 cells. Since U0126 blocks AP-1 signaling through MEK1/2
inhibition [79] and SP600125 blocks c-Jun phosphorylation and
activation of AP-1 through inhibition of JNKs, these results suggest
that the AP-1 pathway is not involved in the reduction of the mCx-
I activity observed in IB3-1 CF cells. Noteworthy, the p38 MAPK
inhibitor SB203580 was able to induce a significant recovery in the
mCx-I activity of IB3-1 cells. The effect was even more
pronounced when the IKK inhibitor III was used, which was
able to fully recover the mCx-I activity of IB3-1 cells compared to
S9 cells.
Regarding the levels of reactive oxygen species (ROS), it has
been reported that under certain conditions a reduced mCx-I
activity might lead to increased levels of mitochondrial (mROS)
[96]. In addition, Velsor et al. [33] found increased mitochondrial
(and cytoplasmic) ROS levels in IB3-1 CF cells (these mitochon-
drial effects in CF were reviewed in [35]). Therefore, we measure
the mitochondrial and cellular ROS levels of IB3-1 cells treated or
not with IL-1b blocking mAb and IL-1b pathway inhibitors. We
found elevated mitochondrial and cellular ROS levels in IB3-1
cells compared to S9 cells. Similarly to the rescued effects on mCx-
I activity, the anti-IL-1b blocking antibody was able to decrease
mitochondrial ROS levels of IB3-1 cells over 50% and the cellular
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ROS levels near 100%. Addition of IL-1b (5 ng/ml) to IB3-1 cells
could not further increase the ROS levels, suggesting again (as
observed for the mCx-I activity) that the IL-1b signaling was
already saturated by the endogenous autocrine secretion of IL-1b.
On the other hand, the inhibitor SB203580 (p38 MAPK) and the
IKK inhibitor III (NF-kB pathway), were both able to produce a
significant reduction of mitochondrial ROS levels in IB3-1 cells (,
30 and 40% respectively) and a reduction to near basal values in
the cellular ROS levels. These results correlate with the effects of
these inhibitors on mCx-I activity. In addition, as occurred with
the mCx-I activity, the AP-1 pathway inhibitors (U0126 and
SP600125) showed not significant differences compared to control
IB3-1 cells, suggesting that the AP-1 signaling pathway is not
involved in the increased ROS levels found in IB3-1 CF cells.
To confirm the results obtained in IB3-1 we developed a
different cellular model, made by using Caco-2 coloncarcinoma
cells. As expected, Caco-2/pRS26 CFTR-shRNA cells showed a
significant reduction in the mitochondrial NADH-cytochrome c
reductase activity compared to Caco-2/pRSctrl control cells.
Incubations with IL-1b (5 ng/ml) resulted in a significant
reduction of mitochondrial NADH-cytochrome c reductase
activity only in Caco-2/pRSctrl control cells (a small but not
significant reduction was observed in Caco-2/pRS26). In addition,
the reduced mCx-I activity of Caco-2/pRS26 cells was recovered
by incubation with the IL-1b blocking mAb and a significant
recovery of the mitochondrial NADH-cytochrome c reductase
activity was observed for Caco-2/pRS26 cells in the presence of
IKK inhibitor III or the p38 MAPK inhibitor SB203580. Also,
elevated ROS levels were found in Caco-2/pRS26 cells compared
to Caco-2/pRSctrl control cells (similar preliminary results were
previously obtained with Caco-2/pRS25 cells [97]). Finally, the
anti-IL-1b blocking antibody decreased ROS levels in this CFTR
impaired cells. Moreover, the IKK inhibitor III and the p38
inhibitor were also able to decrease the ROS levels in Caco-2/
pRS26 cells.
Thus, the results obtained measuring mitochondrial ROS levels
are in agreement with those obtained by using IB3-1 cells, and
confirm the presence of autocrine IL-1b affecting the mCx-I
activity and the ROS levels of cells with impaired CFTR activity
(IB3-1 and Caco-2/pRS26 cells). The alternative possibility of the
absence or reduction of IL-1b receptor levels or signaling in IB3-1
cells should not be ruled-out, although it seems unlikely. In fact,
the IL-1b blocking Ab was able to reduce the cellular ROS levels
near basal values, suggesting that the IL-1b receptor signaling is
not affected in IB3-1 cells (since in the absence of IL-1b blocking
Ab or IL1RN the mCx-I activity and ROS levels are affected by
the secreted IL-1b). Regarding the cellular ROS levels, in addition
to the ROS produced by mitochondria, other sources of ROS
such as the DUOX1/2 system cannot be ruled-out [90]. Since the
recovery obtained in ROS levels using the blocking Ab or the
inhibitors was not total, other mechanisms of ROS generation
might also be contributing to the total ROS levels. We do not
known yet whether the high ROS levels affect the mCx-I activity
or vice versa, the high ROS levels are a consequence of the
reduced mCx-I activity. Probably both possibilities are operating
simultaneously, since it has been shown that a reduced mCx-
activity can induce ROS generation [88,89] and also, the
generation of ROS can reduce the mCx-I activity, since it is
highly susceptible to oxidation [98,99]. In addition, an alternative
scenario for the observed effects on ROS and IL-1b is one in
which CFTR is affecting first the ROS levels, increasing in turn
NF-kB activity and then IL-1b levels (CFTR failure R ROS R
NF-kB R IL-1b). However, it seems also unlikely, since the
stimulation of ROS would be upstream of IL-1b and in such case
the blocking Ab should not be able to reduce the ROS levels, as we
have observed here (unless this alternative mechanisms is
accounting for the remaining mitochondrial ROS levels observed
in the presence of the blocking Ab). Further studies are needed to
determine which is first, ROS, IL-1b or both in parallel. Our
present data rather support the first hypothesis (CFTRR IL-1bR
ROS), although the data are not conclusive yet.
A graphical summary of the results obtained here is shown in
Figure 11, made by using the Pathway Studio software v.9 [100].
The results imply that autocrine IL-1b has a major role in the
reduction of the mCx-I activity observed in cultured CF cells or
cells with impaired CFTR activity (IB3-1, Caco-2/pRS26 cells).
Interestingly, the IKK inhibitor III, the IL-1b blocking Ab or the
IL-1RN, were able to fully restore the mCx-I activity, and to
produce a significant reduction in the ROS levels, to near basal
values for cellular ROS levels. In consequence, IL-1b blocking
reagents and inhibitors of NF-kB or p38 MAPKs might have
therapeutic significance for CF patients. Since the IL-1b autocrine
effects over mCx-I and ROS were observed in cell cultures in the
absence of bacterial infections, the IL-1b autocrine effects appear
to be a primary, intrinsic characteristic of CF cells. However, it
should be pointed out that the results obtained here with IB3-1
and Caco-2/pRS26 cells should not be generalized without
caution. In fact, there is no consensus regarding whether or not CF
cells significantly differ from normal with respect to ROS, NF-kB
activity, and IL1b expression or signaling [27,101-106]. Finally,
the physiological significance of the reduced mCx-I activity and
the increased ROS levels observed for IB3-1 and Caco-2/pRS26
cells is yet unknown.
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